8-KEarnings & Results

BIOGEN INC. 8-K Report, Financial Results (Apr 6, 2026)

Filed April 6, 2026For Securities:BIIB

Summary

Biogen Inc. has filed an 8-K report on April 6, 2026, to provide preliminary insights into its first quarter 2026 financial results. The company anticipates recognizing approximately $34 million in pre-tax acquired in-process research and development (R&D), upfront, and milestone expenses. This is expected to negatively impact both GAAP and non-GAAP earnings per diluted share by approximately $0.19 for the quarter. These expenses are typically associated with collaboration and licensing agreements, including upfront and milestone payments, and can also involve premiums on equity securities or asset acquisitions related to in-process R&D. Biogen notes that such expenses are inherently difficult to forecast due to the unpredictable nature of future transactions. Investors should consider this a preliminary disclosure, as final results are subject to financial statement closing procedures and may differ.

Key Highlights

  • 1Biogen expects approximately $34 million in pre-tax acquired in-process R&D, upfront, and milestone expenses for Q1 2026.
  • 2These expenses are projected to reduce Q1 2026 GAAP and non-GAAP earnings per diluted share by approximately $0.19.
  • 3The expenses are linked to collaboration and license agreements, including upfront/milestone payments.
  • 4Biogen states that these types of expenses are not forecasted due to their unpredictable occurrence, magnitude, and timing.
  • 5The disclosed figures are preliminary estimates and subject to finalization of financial statements.
  • 6Final reported results could differ from these preliminary unaudited estimates.

Frequently Asked Questions

The $34 million expense is related to acquired in-process research and development (R&D), upfront, and milestone costs associated with Biogen's collaboration and license agreements. This can include payments for intellectual property or product candidates, and potentially premiums paid for equity or asset acquisitions within R&D.

Biogen estimates that this expense will reduce both its GAAP and non-GAAP earnings per diluted share by approximately $0.19 for the first quarter of 2026.

Biogen does not typically forecast acquired in-process R&D, upfront, and milestone expenses because their occurrence, size, and timing are highly uncertain and depend on future business development activities and agreements.

No, the figures provided are preliminary and unaudited estimates. Biogen's financial statement closing procedures are still in process, and there is no guarantee that the final reported results for the first quarter of 2026 will not differ from these initial estimates.